Summary of antiplatelet therapy
| Stable | Progression | % Progression | |
|---|---|---|---|
| AS (+), n = 62 | 46 | 16 | 25.8 |
| AS (−), n = 33 | 28 | 5 | 15.2 |
| TI (+), n = 26 | 14 | 12 | 46.2 |
| TI (−), n = 69 | 60 | 9 | 13.0 |
| CL (+), n = 26 | 23 | 3 | 11.5 |
| CL (−), n = 69 | 51 | 18 | 26.1 |
| CIL (+), n = 29 | 27 | 2 | 6.9 |
| CIL (−), n = 66 | 47 | 19 | 28.8 |
Note:—The progression of carotid artery stenosis was significantly less in patients with cilostazol use compared with patients without cilostazol use (P = .03). AS indicates aspirin; TI, ticlopidine; CL, clopidogrel; CIL, cilostazol. Forty-seven patients received single antiplatelet therapy (AS 16, TI 5, CL 14, CIL 12), 48 patients received dual antiplatelet therapy (AS+TI 20, AS+CL 11, AS+CIL 15, TI+CIL 1, CL+CIL 1). The progression of carotid artery stenosis was significantly less in patients with cilostazol use compared with patients without cilostazol use (P = .03).